Bevacizumab

ανά Kazazi-Hyseni, Filis, Beijnen, Jos H., Schellens, Jan H. M.
Έκδοση 2010

Trastuzumab

ανά Boekhout, Annelies H., Beijnen, Jos H., Schellens, Jan H.M.
Έκδοση 2011

Protein versus DNA as a marker for peripheral blood mononuclear cell counting

ανά Jansen, Robert S., Rosing, Hilde, Schellens, Jan H. M., Beijnen, Jos H.
Έκδοση 2009

Concise Drug Review: Azacitidine and Decitabine

ανά Derissen, Ellen J.B., Beijnen, Jos H., Schellens, Jan H.M.
Έκδοση 2013

Inhibitors of mTOR

ανά Klümpen, Heinz-Josef, Beijnen, Jos H., Gurney, Howard, Schellens, Jan H.M.
Έκδοση 2010

Part 3: Pharmacogenetic Variability in Phase II Anticancer Drug Metabolism

ανά Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Έκδοση 2011

Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects

ανά Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Έκδοση 2011

Part 1: Background, Methodology, and Clinical Adoption of Pharmacogenetics

ανά Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Έκδοση 2011

Part 2: Pharmacogenetic Variability in Drug Transport and Phase I Anticancer Drug Metabolism

ανά Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Έκδοση 2011

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients

ανά Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Έκδοση 2013

Lapatinib for Advanced or Metastatic Breast Cancer

ανά Opdam, Frans L., Guchelaar, Henk-Jan, Beijnen, Jos H., Schellens, Jan H.M.
Έκδοση 2012

Concise Drug Review: Pazopanib and Axitinib

ανά van Geel, Robin M.J.M., Beijnen, Jos H., Schellens, Jan H.M.
Έκδοση 2012

Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers

ανά van den Broek, Irene, Sparidans, Rolf W., Schellens, Jan H. M., Beijnen, Jos H.
Έκδοση 2010

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs

ανά Kip, Anke E., Schellens, Jan H. M., Beijnen, Jos H., Dorlo, Thomas P. C.
Τόπος έκδοσης Clin Pharmacokinet (2017)

Treatment Individualization in Colorectal Cancer

ανά van Geel, Robin M. J. M., Beijnen, Jos H., Bernards, René, Schellens, Jan H.M.
Τόπος έκδοσης Curr Colorectal Cancer Rep (2015)

BRAF Mutations as Predictive Biomarker for Response to Anti‐EGFR Monoclonal Antibodies

ανά van Brummelen, Emilie M. J., de Boer, Anthonius, Beijnen, Jos H., Schellens, Jan H. M.
Τόπος έκδοσης Oncologist (2017)

Letter to the Editor Regarding “A Prospective, Controlled Study of the Botanical Compound Mixture LCS101 for Chemotherapy-Induced Hematological Complications in Breast Cancer” by Y...

ανά Mooiman, Kim D., Goey, Andrew K.L., Meijerman, Irma, Beijnen, Jos H., Schellens, Jan H.M.
Έκδοση 2012

Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses

ανά Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.
Έκδοση 2012

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

ανά Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.
Έκδοση 2011

Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges

ανά van Brummelen, Emilie M.J., Ros, Willeke, Wolbink, Gertjan, Beijnen, Jos H., Schellens, Jan H.M.
Τόπος έκδοσης Oncologist (2016)